1Y Close · As of Aug 26, 2026
HLB operates in the Pharmaceuticals sector.
Legal name: HLB Co.,LTD.
In fiscal year 2025, HLB (028300) reported revenue of 84.2 billion KRW, up 23.6% from 68.1 billion KRW a year earlier.
Operating profit was -104.2 billion KRW and net income was -235.4 billion KRW in the same year.
As of the Aug 26, 2026 close, the market capitalization was 4.86 trillion KRW, with a P/B of 9.83.
These figures can be verified in the DART filing (receipt no. 20260323001673).
Financials
| Year | Rev | Op Inc | Net Inc |
|---|---|---|---|
| 2025 | 84.2B | -104.2B | -235.4B |
| 2024 | 68.1B | -118.5B | -108.0B |
| 2023 | 42.9B | -125.0B | -206.0B |
| 2022 | 179.7B | -74.7B | -98.6B |
| 2021 | 69.8B | -101.0B | -111.6B |
Recent Filings
Large Shareholding Report (General)
Officer/Major Shareholder Ownership Report
Securities Issuance Result (Voluntary Disclosure)
Checks
2 of 8 checked items currently applicable.
Market Cap & Price: Market cap is above the delisting threshold.
Audit Opinion: Audit opinion: Unqualified (clean).
Capital Increase: No capital-increase filings in the last 180 days.
Treasury Stock: No treasury stock filings.
Embezzlement & Litigation: No embezzlement or litigation filings in the last 180 days.
Major Shareholder Change: No major shareholder changes in the last 180 days.
Market Action: No market actions recorded in the last 180 days.
Recent Filings
| Date | Filing |
|---|---|
| 2026-08-20 | Large Shareholding Report (General) |
| 2026-08-20 | Officer/Major Shareholder Ownership Report |
| 2026-08-19 | Securities Issuance Result (Voluntary Disclosure) |
| 2026-08-14 | Derivative Trading Loss |
| 2026-08-14 | Semi-Annual Report (2026.06) |